The iShares Biotechnology ETF (XBI) experienced a 5% decline, driven by negative sentiment in the biotech sector. This downturn was attributed to news related to Vertex Pharmaceuticals Inc (VRTX), which impacted the broader biotechnology market. The sector's weakness is also believed to be influenced by concerns over potential pharmaceutical tariff risks being priced in by investors.